title: [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
abstract: Gefitinib and erlotinib are selective epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor. They are approved for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK. We report the case of a hepatitis cytolytic during gefitinib treatment with a positive rechallenge. A relay by erlotinib has been initiated and doesn't give recurrence of hepatotoxicity. From a literature review and this observation, arguments have been provided to justify erlotinib as a safe and well-tolered alternative for patients who have to stop gefitinib after a severe hepatotoxicity.
authors.affiliation: Centre régional de Pharmacovigilance de Grenoble, Pavillon E, CHU de Grenoble, Grenoble, France.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Durand
authors.affiliation: Centre régional de Pharmacovigilance de Grenoble, Pavillon E, CHU de Grenoble, Grenoble, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Logerot
authors.affiliation: Laboratoire de Pharmacologie et Toxicologie, Institut de Biologie et de Pathologie, CHU de Grenoble, Grenoble, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Fonrose
authors.affiliation: Centre régional de Pharmacovigilance de Grenoble, Pavillon E, CHU de Grenoble, Grenoble, France.
authors.forename: Edith
authors.initials: E
authors.lastname: Schir
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D056486:Chemical and Drug Induced Liver Injury / Q000628:therapy; D057915:Drug Substitution; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib